Laparoscopic radical cystectomy (LRC) is a challenging technique, but it has been proposed as an alternative to open radical cystectomy (ORC), which is currently the gold standard treatment for muscle ...
South Wales Argus on MSN
Ketamine group aims to reduce pressure on NHS from illegal drug use
A SPECIALIST group established in response to an increase in ketamine use is intended to prevent users needing hospital ...
ImmunityBio's Anktiva wins conditional EMA approval, but faces stiff competition and financial risks. Click for why IBRX ...
While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...
Gene Holdings Inc. rises on 62% CR rate in Phase 2 NMIBC trial. Click to learn about ENGN and its gene delivery tech, market ...
Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...
US biotech ImmunityBio announced that treatment with Anktiva (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months, including disease-free ...
Astellas Pharma announces positive topline results from phase 3 EV-304 clinical trial of Padcev plus Keytruda: Tokyo Friday, December 19, 2025, 10:00 Hrs [IST] Astellas Pharma Inc ...
Medtronic plc (NYSE:MDT) is one of the best healthcare AI stocks to buy now. On December 4, Stifel reaffirmed its Hold rating ...
Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone.
ImmunityBio Inc. (NASDAQ: IBRX) is one of the best multibagger penny stocks to buy right now. On December 12, analysts at Jefferies raised the stock’s price target to $9 from 8 while reiterating a Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback